Breaking News
December 14, 2017 - Living Lyme disease bacteria found months after antibiotic treatment
December 14, 2017 - These annual checkups help seniors not only survive but thrive
December 14, 2017 - Study reveals impact of diabetes during pregnancy on baby’s heart
December 14, 2017 - Huntington’s disease drug clears initial hurdles
December 14, 2017 - TPU researchers create 3D-printed models of children’s hearts
December 14, 2017 - Brain responses of children with inherited dyslexia risk predict their future reading speed
December 14, 2017 - Study: New Furosemide Formulation Simplifies Administration for HF
December 14, 2017 - Discrimination harms your health—and your partner’s
December 14, 2017 - Having older brothers may increase the likelihood of being gay
December 14, 2017 - New scientific yardstick released to help early detection of Alzheimer’s disease
December 14, 2017 - New finding demonstrates what happens at cellular level during onset of type2 diabetes
December 14, 2017 - Study identifies potassium as key to circadian rhythms in red blood cells
December 14, 2017 - NIH expected to award up to $70 million to launch Alzheimer’s Clinical Trials Consortium
December 14, 2017 - Pitting pathogens against each other could prevent drug resistance emerging
December 14, 2017 - Study provides new insights into development of Sonic Hedgehog medulloblastoma
December 14, 2017 - Dr. Reddy’s Announces Approval of Impoyz (clobetasol propionate) Cream for Plaque Psoriasis
December 14, 2017 - Gene Screens Can Alter Perception, Behavior
December 14, 2017 - Can Scrotal Vein Condition Hike Heart Risks?: MedlinePlus Health News
December 14, 2017 - Molecules in spit may be able to diagnose and predict length of concussions
December 14, 2017 - Children’s Colorado and RxRevu partner to help prescribers better meet needs of pediatric patients
December 14, 2017 - Researchers discover new way to attack drug-resistant prostate cancer cells
December 14, 2017 - Scientists develop new, high resolution method for identifying microbial species and strains
December 14, 2017 - Declining trend of salmonellosis cases has leveled off in the EU
December 14, 2017 - Death receptors in the blood can help measure risk of cardiovascular diseases, type 2 diabetes
December 14, 2017 - How to Perk Up the Holidays for Hospital Patients
December 14, 2017 - Prolonged Sedation May be Bad for Baby’s Brain
December 14, 2017 - The pediatric submersion score predicts children at low risk for injury following submersions
December 14, 2017 - Video game helps doctors to quickly recognize trauma patients who need high levels of care
December 14, 2017 - Younger persons newly-diagnosed with type 2 diabetes have poorer health than older patients
December 14, 2017 - Clinician re-examines evidence on re-use of catheters and UTIs in people with spinal cord injuries
December 14, 2017 - UK and Russian researchers join forces against AMR
December 14, 2017 - Results of Bariatric Surgery Hold Up Over Time
December 14, 2017 - High-intensity exercise delays Parkinson’s progression
December 14, 2017 - Protein structure could pave way for effective drugs to treat cystic fibrosis
December 14, 2017 - Minority people less likely to see dermatologist for psoriasis treatment
December 14, 2017 - Study indicates decline in use of chemotherapy for early stage breast cancer patients
December 14, 2017 - Chagas disease presents real public health problem to Canadians
December 14, 2017 - Experts call for rigorous clinical trials in use of experimental fetal therapy
December 14, 2017 - Lactic acid bacteria can offer protection against subtypes of influenza A virus
December 14, 2017 - Tapeworm drug could provide new hope for patients with Parkinson’s disease
December 14, 2017 - Parkinson’s progression delayed through high-intensity exercise, study says
December 14, 2017 - Researchers discover potential regulator essential for killer T cells to reside in tumors
December 14, 2017 - Tailor-made protein combats several kinds of pathogenic bacteria
December 14, 2017 - Hidden genes hold blueprints for designing new anti-cancer drugs
December 14, 2017 - Male virgins still at risk for acquiring HPV, study finds
December 14, 2017 - Study reveals novel molecular targets to improve chemotherapy’s efficiency against leukemia
December 14, 2017 - Talazoparib Significantly Extends Progression-Free Survival in Phase 3 EMBRACA Trial of Patients with Metastatic Breast Cancer
December 14, 2017 - AHA: Hospital QI Initiative Fails to Budge Outcomes in India
December 14, 2017 - Scientists observe tremors associated with Parkinson’s disease in fruit flies
December 14, 2017 - Newly discovered molecular chaperones may soon be part of therapies for Huntington’s disease
December 14, 2017 - Performing surgery on virtual patient could provide valuable insight into consequences
December 13, 2017 - New insights into mosquito sex protein could provide strategies to control diseases
December 13, 2017 - Lilly’s Taltz (ixekizumab) Receives U.S. FDA Approval for the Treatment of Active Psoriatic Arthritis
December 13, 2017 - Step Into Sunshine | Medpage Today
December 13, 2017 - Poor Prognosis for Diabetic Foot Sores: MedlinePlus Health News
December 13, 2017 - Exercise alone does not lead to weight loss in women—in the medium term
December 13, 2017 - Researchers use new approach to identify casual mechanisms in depression
December 13, 2017 - Genetic Analysis and Bio-Rad enter into supply and distribution agreement for GA-map clinical test
December 13, 2017 - Study finds barriers to stem cell transplant use among multiple myeloma patients from minority groups
December 13, 2017 - Scientists discover how axons in developing visual system stabilize their connections
December 13, 2017 - Novel compound inhibits mycomembrane biosynthesis and kills tuberculosis bacteria
December 13, 2017 - FDA Launches New Tool for Sharing Information That Allows Doctors to Better Manage Antibiotic Use
December 13, 2017 - Evolocumab Wins FDA Approval for Stand-Alone CVD Prevention
December 13, 2017 - Powerful Clot-Busting Drugs Not Useful After Leg Blockages: Study: MedlinePlus Health News
December 13, 2017 - The fight against obesity: To tax or not to tax?
December 13, 2017 - Isolation during holidays can impact health of seniors
December 13, 2017 - Specialized physiotherapy provides many benefits for patients with Parkinson’s disease
December 13, 2017 - Pairing immunotherapy drug with chemotherapy proves beneficial for relapsed acute myeloid leukemia
December 13, 2017 - Researchers find link between brain structure and hallucination proneness, musical aptitude
December 13, 2017 - Radiation responsive molecules derived from horse chestnuts aid cancer imaging
December 13, 2017 - New Gene Therapy May Be Cure for ‘Bubble Boy’ Disease
December 13, 2017 - MorningBreak: Insurance Driving Drug Prices? Crunch Time for ACA; The ‘Other’ Drug Problem
December 13, 2017 - Are Stents Really Useless After Chest Pain? Cardiologists Not Sure: MedlinePlus Health News
December 13, 2017 - Can you train yourself to develop ‘super senses’?
December 13, 2017 - Cellular self-digestion process plays role in development of autoimmune diseases
December 13, 2017 - E-cigarette use among youth leads to smoking as adults finds study
December 13, 2017 - New nanomaterial could enable new types of chemical processes in pharma, materials and chemical industries
December 13, 2017 - Another CGRP Drug Gains Ground in Migraine
December 13, 2017 - Trigger for most common form of vision loss discovered
December 13, 2017 - Study reveals link between estrogen and infertility
Introduction is different, but top medications for opioid addiction equally effective

Introduction is different, but top medications for opioid addiction equally effective

image_pdfDownload PDFimage_print
Research from NYU School of Medicine, led by John Rotrosen, MD (left), from the Department of Psychiatry, and Joshua D. Lee, MD, MSc, from the Department of Population Health, examined in a head-to-head study two popular medications to treat opioid addiction. Credit: NYU Langone Health

With opioid addiction officially declared a public health emergency in the U.S., medical intervention to treat the illness is increasingly important in responding to the epidemic. Now, a new study concludes that two of the top medications available for outpatient, office-based treatment, once initiated, are equally safe and effective in curtailing opioid use, relapse, treatment drop-out and overdose.

Researchers in the Departments of Psychiatry and Population Health at NYU School of Medicine, who led the study sponsored by the National Institute on Drug Abuse (NIDA) and published online November 14, 2017 in The Lancet, conclude that extended-release naltrexone (an opioid antagonist marketed as Vivitrol) demonstrated similar safety and clinical effectiveness to more commonly prescribed buprenorphine-naloxone (an opioid agonist marketed both generically and as Suboxone).

However, the study also points out differences that have previously been known: Patients being treated with naltrexone must detoxify before it can be administered. (This is commonly referred to as the “detox hurdle.”) On the other hand, buprenorphine allows individuals to transition relatively seamlessly from opioid use to medication maintenance without needing to detoxify.

Agonist (buprenorphine) and antagonist (naltrexone) treatment are pharmacologically, conceptually and logistically near-opposites—allowing patients, families and providers to choose an approach in line with their goals and preferences. Among the differences:

  • Agonists activate opioid receptors, have opioid-like effects, and maintain physical dependence on opioids, while antagonists have no effects on their own and block the effects of opioids
  • Agonists can be started while a patient is still opioid dependent or detoxifying, but antagonists only can be administered after full detoxification to avoid opioid withdrawals
  • When discontinued, agonists are associated with withdrawal symptoms; antagonists are not
  • Agonists have abuse potential and diversion risks; antagonists do not
  • There are differences in prescribing regulations and community acceptance between the two forms of treatment

Despite these differences, the researchers say, until now there had been no comparative data on the effectiveness of both treatments. “As the epidemic has escalated, and hundreds of people in the U.S. and elsewhere are dying every day, there is an increased urgency to provide immediate and effective medical treatment,” says John Rotrosen, MD, professor in the Department of Psychiatry at NYU School of Medicine and the study’s senior author. “Our findings should dispel some commonly held misconceptions and help patients choose between these different approaches to treatment.”

Co-investigator Joshua D. Lee, MD, MSc, from the Department of Population Health at NYU School of Medicine, describes research examining in a head-to-head study two popular medications to treat opioid addiction. Credit: NYU Langone Health

What the Study Examined

The clinical trial took place from 2014 to 2017 at eight community treatment programs affiliated with NIDA’s Clinical Trials Network across the U.S. The patient cohort involved 570 opioid dependent adults, approximately two-thirds of whom were men and 82% primarily using heroin. They were recruited during admission for detoxification and randomly assigned to two study groups for up to 24 weeks of treatment. One group received a monthly injection of naltrexone initiated after completing detoxification, and the other self-administered a daily oral dose of buprenorphine initiated as early as possible after randomization.

Among those treated, 24-week relapse rates were similar—52% for naltrexone and 55.6% for buprenorphine, as were other measures of opioid use. In addition, craving for opioids was lower with naltrexone, though by the end of 24 weeks, the buprenorphine group had caught up. Other than mild to moderate injection site reactions with naltrexone, adverse events, including fatal and non-fatal overdoses, were similar across the two study groups.

The study also examined the detox hurdle—a critical point of initiation for active users (though a non-issue for those who are already fully detoxed). Approximately 25% of participants assigned to the naltrexone group were unable to complete detox and get a first dose of naltrexone—though for those assigned to naltrexone later in the detox process, the hurdle wasn’t so insurmountable. In contrast, only 6%, of patients were unable to start buprenorphine.

The study could have immediate implications for how the U.S. responds to a crisis that has already claimed 300,000 lives since 2000, according to the U.S. Centers for Disease Control and Prevention.

“Both medications are effective treatments for opioid use disorders versus counseling-only approaches or compared to placebo,” says Joshua D. Lee, MD, MSc, associate professor in the Departments of Medicine and Population Health at NYU School of Medicine and the study’s lead author. “What is now clear is how similar the outcomes are for those initiating treatment with either medication.”

The researchers also point out that the study sheds light on the likelihood that those dropping out of detox will rapidly relapse. “Patients wanting naltrexone, but who are unable to complete detox,” Lee adds, “should be encouraged to start an agonist-based treatment like buprenorphine.”

A smaller (total cohort of 159 patients) and shorter (up to 12 weeks of treatment) parallel study conducted in Norway over the same period found naltrexone and buprenorphine to be equally effective in retaining patients in treatment and reducing opioid use. However, all participants in that study were randomized late in detox so there was no “hurdle” to clear. Prior to these two studies, the field had no comparative effectiveness data. An earlier multi-site clinical trial led by NYU School of Medicine found in 2016 that extended-release Naltrexone was effective at preventing opioid relapse in criminal justice offenders.


Explore further:
Extended-release naltrexone promising for opioid dependence

More information:
“Medications for opioid use disorder: bridging the gap in care,” The Lancet (2017). www.thelancet.com/journals/lan … ulltext?elsca1=tlxpr

Journal reference:
The Lancet

Provided by:
NYU Langone Health

Tagged with:

About author

Related Articles